Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-250-5 | CAS number: 80-09-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7 mg/m³
- Most sensitive endpoint:
- developmental toxicity / teratogenicity
- Route of original study:
- Oral
DNEL related information
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 176 mg/m³
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 10 mg/kg bw/day
- Most sensitive endpoint:
- developmental toxicity / teratogenicity
- Route of original study:
- Oral
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 200 mg/kg bw/day
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Acute/short-term exposure - systemic effects
According to the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health", a DNEL for acute systemic toxicity should only be derived if an acute systemic toxicity hazard leading to classification is identified.
Referring to the available data on acute toxicity, 4,4'-sulphonyldiphenol displays low acute toxicity as evidenced by an LD50 value of 2830 mg/kg bw determined in rats for the oral route. A weight of evidence for the dermal route of exposure is indicating a similar low acute toxicity with a LD50 value well above 2000 mg/kg bw. No experimental data for the inhalation route is available.
Therefore, 4,4'-sulphonyldiphenol is not subject to classification for acute toxicity according to Directive 67/548/EEC and Regulation No 1272/2008, and consequently the derivation of worker DNELs for acute/short-term exposure - systemic effects is not required.
Acute/short-term and long-term exposure - local effects
Based on the available toxicological information, 4,4'-sulphonyldiphenol is not subject to classification for skin, eye and/or respiratory irritation and no worker DNEL for local effects following acute/short-term or long-term exposure is derived. In addition no skin sensitizing properties were observed.
This is in line with the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health".
Long-term exposure - systemic effects
All three available oral repeated dose toxicity studies with rats well reflect common features of toxicity (see repeated dose toxicity: oral). Effect levels (LOAELs) were consistently at or above 200 mg/kg bw. The study with the longest exposure (sub-chronic, 90 day) is regarded as the most relevant study to derive a point of departure (NOAEL) for human health risk assessment.
In this study 4,4´-sulphonyldiphenol was administered by gavage to groups of 10 male and 10 female Wistar rats at dose levels of 0, 100, 300 and 1000 mg/kg bw/d (BASF SE, 2014). Due to a severely impaired body weight development in male animals of the high dose group, i.e. -20% on study day 63, the male animals were treated at a dose level of 600 mg/kg bw/d from study day 70 onwards. Female animals were continuously treated at the limit dose. 100mg/kg bw was identified as an overall NOAEL based on an adverse decrease in male body weights and histopathological lesions in the mammary gland observed in male animals of the mid dose group (300 mg/kg bw).
Adaptation of the starting point - inhalation:
In order to derive a worker DNEL and under the assumption of a daily exposure period of 8 hours, the oral NO(A)EL is converted into an inhalation NO(A)EC according to the following formula:
inhalation NO(A)EC = oral NO(A)EL × 1/sRV(rat) × ABSoral(rat)/ABSinhalation(human) × sRV(human)/wRV(human)
with:
oral NO(A)EL: 100 mg/kg bw/day (from subchronic study, see above)
sRV(rat): 0.38 m³/kg bw (8 hours) [standard respiratory volume of the rat]
ABSoral(rat)/ABSinhalation(human): 1 [ratio of oral absorption in the rat to inhalative absorption in the human], high rates of bioavailability via the lung can e.g occur for substances which can penetrate into the lower/alveolar region and well solubilize in the bonchioalveolar fluid. 4,4´-sulphonyldiphenol is a solid granula with a rather low solubility and only a minor share of the particles is in the respirable range (e.g. <4µm). Larger particles deposit in the upper/thoracic region of the respiratory tract in which an effective retrograde mucocilliary transport exists (see toxicokinetics). This is justifying a very conservative deviation from the ECHA guidance factor of 0.5 by anticipating an equal bioavailability in the respiratory- in comparison to the gastrointestinal- tract.
sRV(human)/wRV(human): 6.7 m³/10 m³ [ratio of human standard respiratory volume to worker respiratory volume]
Accordingly, the oral NO(A)EL of 100 mg/kg bw/day is transformed in an inhalation NO(A)EC of 176 mg/m³.
The following assessment factors are used for the derivation the worker DNEL for inhalation exposure to 4,4'-Sulfonyldiphenol:
Interspecies factor (rat to human): 1 (external concentration)
Remaining differences: 2.5
Intraspecies factor (worker): 5
Exposure duration factor: 2 (subchronic to chronic)
Dose-response factor: 1
Quality of whole database factor: 1
The resulting worker DNEL inhalation is:
worker DNEL (inhalation exposure) = 176 mg/m³ / (2.5 x 5 × 2 × 1 × 1) = 7 mg/m³
As indicated this DNEL is refering to the systemic toxicity of 4,4'-Sulfonyldiphenol. Since the neat substance is a granular solid a potential impairment of the respiratory tract due to exposure to the dust additionally needs to be taken into account. E.g. the German Committee for Dangerous Substances derived a general limit value for low soluble dusts of 1.5 mg/m3 for the alveolar and 10 mg/m3 for the inhalable fraction.
Adaptation of the starting point - dermal:
In order to derive a worker DNEL a worst case dermal absorption rate of 50 % is assumed for 4,4'-Sulfonyldiphenol based on physico/chemical data (solid, low log Pow of 1.2, water solubility of 1.1 g/L; see toxicokinetics). This leads to a NOAEL dermal of 200 mg/kg bw/day.
The following assessment factors are used for the derivation the worker DNEL for dermal exposure to 4,4'-Sulfonyldiphenol:
Interspecies factor (rat to human): 4
Remaining differences: 2.5
Intraspecies factor (worker): 5
Exposure duration factor: 2 (subchronic to chronic)
Dose-response factor: 1
Quality of whole database factor: 1
worker DNEL (dermal exposure) = 200 mg/kg bw/day / (4 x 2.5 × 5 × 2 × 1 × 1) = 20 mg/kg bw/day.
This is in line with the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health".
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.7 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 87 mg/m³
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 200 mg/kg bw/day
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 100 mg/kg bw/day
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Acute/short-term exposure - systemic effects
According to the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health", a DNEL for acute systemic toxicity should only be derived if an acute systemic toxicity hazard leading to classification is identified.
Referring to the available data on acute toxicity, 4,4'-sulphonyldiphenol displays low acute toxicity as evidenced by an LD50 value of 2830 mg/kg bw determined in rats for the oral route. A weight of evidence for the dermal route of exposure is indicating a similar low acute toxicity with a LD50 value well above 2000 mg/kg bw. No experimental data for the inhalation route is available.
Therefore, 4,4'-sulphonyldiphenol is not subject to classification for acute toxicity according to Directive 67/548/EEC and Regulation No 1272/2008, and consequently the derivation of general population DNELs for acute/short-term exposure - systemic effects is not required.
Acute/short-term and long-term exposure - local effects
Based on the available toxicological information, 4,4'-sulphonyldiphenol is not subject to classification for skin, eye and/or respiratory irritation and no general population DNEL for local effects following acute/short-term or long-term exposure is derived. In addition no skin sensitizing properties were observed.
This is in line with the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health".
Long-term exposure - systemic effects
All three available oral repeated dose toxicity studies with rats well reflect common features of toxicity (see repeated dose toxicity: oral). Effect levels (LOAELs) were consistently at or above 200 mg/kg bw. The study with the longest exposure (sub-chronic, 90 day) is regarded as the most relevant study to derive a point of departure (NOAEL) for human health risk assessment.
In this study 4,4´-sulphonyldiphenol was administered by gavage to groups of 10 male and 10 female Wistar rats at dose levels of 0, 100, 300 and 1000 mg/kg bw/d (BASF SE, 2014). Due to a severely impaired body weight development in male animals of the high dose group, i.e. -20% on study day 63, the male animals were treated at a dose level of 600 mg/kg bw/d from study day 70 onwards. Female animals were continuously treated at the limit dose. 100mg/kg bw was identified as an overall NOAEL based on an adverse decrease in male body weights and histopathological lesions in the mammary gland observed in male animals of the mid dose group (300 mg/kg bw).
Adaptation of the starting point - inhalation:
In order to derive a general population DNEL and under the assumption of a daily exposure period of 24 hours, the oral NO(A)EL is converted into an inhalation NO(A)EC according to the following formula:
inhalation NO(A)EC = oral NO(A)EL × 1/sRV(rat) × ABSoral(rat)/ABSinhalation(human)
with:
oral NO(A)EL: 100 mg/kg bw/day (from subchronic study, see above)
sRV(rat): 1.15 m³/kg bw (24 hours) [standard respiratory volume of the rat]
ABSoral(rat)/ABSinhalation(human): 1 [ratio of oral absorption in the rat to inhalative absorption in the human]
High rates of bioavailability via the lung can e.g occur for substances which can penetrate into the lower/alveolar region and well solubilize in the bonchioalveolar fluid. 4,4´-sulphonyldiphenol is a solid granula with a rather low solubility and only a minor share of the particles is in the respirable range (e.g. <4µm). Larger particles deposit in the upper/thoracic region of the respiratory tract in which an effective retrograde mucocilliary transport exists (see toxicokinetics). This is justifying a very conservative deviation from the ECHA guidance factor of 0.5 by anticipating an equal bioavailability in the respiratory- in comparison to the gastrointestinal- tract.
Accordingly, the oral NO(A)EL of 100 mg/kg bw/day is transformed in an inhalation NO(A)EC of 87 mg/m³.
The following assessment factors are used for the derivation the general population DNEL for inhalation exposure to 4,4'-Sulfonyldiphenol:
Interspecies factor (rat to human): 1 (external concentration)
Remaining differences: 2.5
Intraspecies factor (general population): 10
Exposure duration factor: 2 (subchronic to chronic)
Dose-response factor: 1
Quality of whole database factor: 1
The resulting general population DNEL inhalation is:
General population DNEL (inhalation exposure) = 87 mg/m³ / (2.5 x 10 × 2 × 1 × 1) = 1.7 mg/m³
Adaptation of the starting point - dermal:
In order to derive a general population DNEL a worst case dermal absorption rate of 50 % is assumed for 4,4'-Sulfonyldiphenol based on physico/chemical data (solid, low log Pow of 1.2, water solubility of 1.1 g/L; see toxicokinetics). This leads to a NOAEL dermal of 200 mg/kg bw/day.
The following assessment factors are used for the derivation the general population DNEL for dermal and oral exposure to 4,4'-Sulfonyldiphenol:
Interspecies factor (rat to human): 4
Remaining differences: 2.5
Intraspecies factor (general population): 10
Exposure duration factor: 2 (subchronic to chronic)
Dose-response factor: 1
Quality of whole database factor: 1
general population DNEL (dermal exposure) = 200 mg/kg bw/day / (4 x 2.5 × 10 × 2 × 1 × 1) = 1 mg/kg bw/day.
general population DNEL (oral exposure) = 100 mg/kg bw/day / (4 x 2.5 × 10 × 2 × 1 × 1) = 0.5 mg/kg bw/day.
This is in line with the ECHA document "Guidance on information requirements and chemical safety assessment, Chapter R.8: Characterisation of dose [concentration]-response for human health".
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1